MarketBeat Week in Review – 05/18 – 05/22 Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results.
Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth portfolio generated more than $1 billion in quarterly revenue, up 24% from the prior-year period
Chief Executive Officer Chris Viehbacher said Biogen’s growth portfolio now exceeds its legacy multiple sclerosis portfolio. He cited the rollout of high-dose SPINRAZA, the expansion of LEQEMBI IQLIK home dosing, and the addition of Apellis products SYFOVRE and EMPAVELI as key components of the company’s strategy to return to sustainable revenue growth. Growth Products Lead Quarterly Performance – Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Chief Financial Officer Robin Kramer said revenue from Biogen’s standalone growth products, excluding the acquired Apellis brands, was $933 million, up 9% year over year.
SYFOVRE and EMPAVELI contributed a combined $128 million in revenue from the May 14 acquisition closing date through the end of the quarter. – SPINRAZA: Revenue was $402 million, up 2% year over year and 7% sequentially. Kramer said results reflected demand and stocking for the high-dose regimen in the U.S., partly offset by shipment timing in certain international markets. – VUMERITY: Revenue was $197 million, down 7% year over year but up 10% sequentially. The year-over-year decline was partly attributed to inventory dynamics. – LEQEMBI: In-market revenue was $184 million, increasing 15% year over year and 9% from the first quarter, supported by market growth in the U.S., Japan and China. – SKYCLARYS: Revenue rose 29% year over year to $168 million.